Relapsed/refractory diffuse large B-cell lymphoma
JW Friedberg - Hematology 2010, the American Society of …, 2011 - ashpublications.org
Despite overall improvements in outcomes of diffuse large B-cell lymphoma (DLBCL),
approximately one-third of patients will develop relapsed/refractory disease that remains a …
approximately one-third of patients will develop relapsed/refractory disease that remains a …
Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma
KM McCarten, HR Nadel, BL Shulkin, SY Cho - Pediatric radiology, 2019 - Springer
Hodgkin lymphoma and non-Hodgkin lymphoma are common malignancies in children and
are now highly treatable. Imaging plays a major role in diagnosis, staging and response …
are now highly treatable. Imaging plays a major role in diagnosis, staging and response …
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
M Roschewski, K Dunleavy, S Pittaluga… - The Lancet …, 2015 - thelancet.com
Background Diffuse large-B-cell lymphoma is curable, but when treatment fails, outcome is
poor. Although imaging can help to identify patients at risk of treatment failure, they are often …
poor. Although imaging can help to identify patients at risk of treatment failure, they are often …
International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers
A Biggi, A Gallamini, S Chauvie… - Journal of Nuclear …, 2013 - Soc Nuclear Med
At present, there are no standard criteria that have been validated for interim PET reporting
in lymphoma. In 2009, an international workshop attended by hematologists and nuclear …
in lymphoma. In 2009, an international workshop attended by hematologists and nuclear …
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
SF Barrington, W Qian, EJ Somer… - European journal of …, 2010 - Springer
Purpose To determine if PET reporting criteria for the Response Adapted Treatment in
Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached …
Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached …
Role of functional imaging in the management of lymphoma
BD Cheson - Journal of Clinical Oncology, 2011 - ascopubs.org
18-F-fluorodeoxyglucose (FDG)–positron emission tomography (PET), and more recently
PET/computed tomography (CT), is the most sensitive and specific imaging technique …
PET/computed tomography (CT), is the most sensitive and specific imaging technique …
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
E Itti, M Meignan, A Berriolo-Riedinger, A Biggi… - European journal of …, 2013 - Springer
Purpose The role of interim PET/CT in guiding therapeutic strategies in diffuse large B-cell
lymphoma (DLBCL) is debated, mainly because interpretation rules vary among centres …
lymphoma (DLBCL) is debated, mainly because interpretation rules vary among centres …
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
RO Casasnovas, M Meignan… - Blood, The Journal …, 2011 - ashpublications.org
The prognostic value of interim positron emission tomography (PET) interpreted according to
visual criteria is a matter of debate in diffuse large B-cell lymphoma (DLBCL). Maximal …
visual criteria is a matter of debate in diffuse large B-cell lymphoma (DLBCL). Maximal …
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
P Pregno, A Chiappella, M Bellò, B Botto… - Blood, The Journal …, 2012 - ashpublications.org
Role of interim-PET (I-PET) in diffuse large B-cell Lymphoma (DLBCL) is controversial. To
determine predictive value of I-PET on progression-free survival (PFS), we enrolled 88 first …
determine predictive value of I-PET on progression-free survival (PFS), we enrolled 88 first …
Cancer biomarkers: selecting the right drug for the right patient
GJ Kelloff, CC Sigman - Nature reviews Drug discovery, 2012 - nature.com
This Perspective highlights biomarkers that are expressed as a consequence of cancer
development and progression. We focus on those biomarkers that are most relevant for …
development and progression. We focus on those biomarkers that are most relevant for …